Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.

Slides:



Advertisements
Similar presentations
Adverse Events and Serious Adverse Events
Advertisements

Safety Reporting IN Clinical Trials
ADVERSE EVENT REPORTING
Biologics for Children with Rheumatic Diseases An Introduction.
2012 UPDATE. What guidelines do we have available to follow for asthma 1) Asthma GP monitoring Guideline 2) Asthma Diagnosis Guideline 3) Acute asthma.
Improved access to medicines 1. Impact of the “Crown Report” Broadening the public’s access to medicines Pre-Crown report – Medically qualified doctor.
Serious Adverse Events
Launch Event – 6 th November 2014 Trial Information and Design Isabel Rubie – Trial Manager The NAtional Trial of Tonsillectomy IN Adults: a clinical and.
Pharmacovigilance Dr. Muiris Dowling,
Adverse Event Reporting. Reporting Adverse Events Adverse Events (AEs) are “... any untoward medical occurrence in a subject that was not previously identified.
SAE Reconciliation How to handle ‘a waterfall’ of SAEs?
{ ADVERSE DRUG REACTIONS To ensure patient, family/caregiver and home health personnel are instructed to identify adverse reactions to medications and.
Elements of a clinical trial research protocol
Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs
Capturing and Reporting Adverse Events in Clinical Research
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
The Medical System. The Health Care System This includes all available medical services, the ways in which individuals pay for medical care, and aimed.
BADBIR BAD Biologic Interventions Register Dr Kathy McElhone 27 th June 2012.
BAD Biologic Interventions Register (BADBIR ) An update November 2010.
The early use of Antibiotics in at Risk CHildren with InfluEnza Chief Investigator: Dr Kay Wang Senior Trial.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
Section 24.1 The Healthcare System Slide 1 of 33 Objectives Identify the healthcare providers that work together to care for patients. Describe different.
Preparing for Maestro Care.  Objective for This Module: At the end of this section, the participant will be able to update the patient history and understand.
British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
Adverse Event Reporting.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
SAE Reporting Judy Breed, BA, RN June, 2011 CONFIDENTIAL.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
BAD Biologic Interventions Register (BADBIR ) An update November 2009.
By: Nicole Bojanowski and Marc Joe
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
Adverse Event Reporting & SAE Reporting for Investigators Trial Number: (POLO-AML-2) Date of training:23 February 2013 Trainer: Deepa Sachdev Venue:Investigator.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
1 IRIS Initiative to Reduce the Impact of Schizophrenia DON’T DELAY! IT’S TIME TO REDUCE THE IMPACT OF PSYCHOSIS IN YOUNG PEOPLE……. NOW!
Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) SAR/SUSAR Mette Krag Dept. of Intensive Care 4131 Copenhagen University Hospital Rigshospitalet,
Health Insurance Question: Why should I have health insurance? The cost of health care has risen drastically over the past few decades. If you do not have.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
Documentation in Practice Dept. of Clinical Pharmacy.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
Antibiotics ‘The Ticking Time Bomb’ Lucy Reid Head of Medicines Management NHS Halton CCG.
Medicines Authority 203,Level 3, Rue D’Argens, Gzira,GZR 1368 Tel: (+356) Fax: (+356) ov.mt Reporting.
REPORTING ADVERSE EVENTS AND COMPLETING THE REPORT FORM
Palliative Care: Emergency Room Interaction
Assessing expectedness of an adverse event
8. Causality assessment:
Safety Reporting Nichol McBee, MPH, CCRP.
Expedited Adverse Event Reporting Requirements
Remote Monitoring of Adverse Events
Meadowbridge Surgery Policy for prescribing of over-the-counter medicines In line with the NI Department of Health and from the 1st May 2017 this practice.
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Pharmacovigilance in clinical trials
Expedited Adverse Event Reporting Requirements
Patient Medical Records
*Continue on SAE supplemental page CTT21 A if more space is required
9. Introduction to signal detection
Remote Monitoring of Adverse Events
Pharmacovigilance (PV)
Patient details Health number: this may be a national identifier (preferred), hospital, clinic, or program number Name: full name is preferable as an accurate.
Adverse Event Reporting _____________________________
Dr Tim England TICH-2 SAE adjudicator
Adverse Event Analysis
Serious Adverse Event Reconciliation
Presentation transcript:

Collecting data in clinic

 Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes  Examples of questions to ask patients  Conclusion

 To investigate the long-term outcome of psoriasis patients treated with biologic agents, with particular reference to safety  Primary endpoints of interest  malignancy  infection requiring hospitalisation  serious adverse events  death

 Any untoward medical occurrence which affects the patient’s health whilst he/she is on BADBIR ◦ e.g. Any new illness, diagnosis, symptoms, accidents, drug reactions, side effects, clinically significant lab results, hospitalisations, surgery including elective, exacerbations of any illness  Does not necessarily have causal relationship with treatment  Applies equally to Conventional Cohort and Biologic Cohort even if the patient is not currently on any systemic treatment

An event is serious if it results in..  Death  Overnight hospitalisation / prolonging an existing hospitalisation  Significant loss of function or disability  Congenital malformation  Life threatening (immediately)  IV antibiotics / antifungals or antivirals  Medically important event (events of special interest)

 Frequently the person entering the data for BADBIR has not reviewed the patient in clinic; the data is collected via a case note review.  This review period may relate to a year or more of the entire patient case notes (not just the dermatology section)  It is essential that all adverse events are accurately recorded (with dates if possible) in the hospital case notes so that these can be entered onto the BADBIR database  It is important to ask the patient whether they suffered any adverse events at each BADBIR follow-up as those not requiring a hospital visit or appointment may not be recorded in the patient notes

Use a specific timeframe with the last BADBIR follow up date as a guide e.g. within the past 6 months Use clear and concise questions Ask the patient to be as specific as possible with dates, when the event occurred and for how long

Ask the patient: ◦ If they suffered from any new illness even if they did not see a doctor - give examples including common coughs and colds ◦ If they suffered relapses /exacerbations of any ongoing illnesses ◦ If they attended any new GP or hospital appointments including visits to the Emergency Department? (might have resulted in a new diagnosis) ◦ If they had any overnight stays in hospital ◦ If they were prescribed any new medication or changes in current medication and why - include over the counter medicines

 Doctor: “How have you been feeling since your last appointment?”  Patient: “Apart from a cold last week, fine.” Limiting the question or keeping it too broad will often result in the patient not providing an accurate account of the adverse events.

 Doctor: “Since your last appointment had you suffered any new illnesses, coughs, colds? Have you had any new appointments with your GP or hospital? Have you been prescribed any new medication or changed what you were previously on?”  Patient: “Yes, I had 3 bouts of colds and a chest infection, which I saw my GP about. He prescribed me antibiotics.” Asking specific questions and providing examples will help the patient understand the question and help them recall any adverse events that occurred.

Adverse Event Information collected on the BADBIR database at each patient follow up This level of detail needs to be recorded in the patient notes The amount of data collected often depends on the information available within the medical notes

 Without accurate and complete adverse event data, safety analysis for the register could be incomplete  Patients needs to be asked specific questions about their health since their last follow-up  All adverse events need to be recorded whether or not they are related to the patient’s skin therapy (biologic or conventional)  All adverse events need to be documented accurately in the case notes